DARA BioSciences, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of oncology treatment and supportive care pharmaceutical products in the United Sates. Its products include Soltamox for the treatment of breast cancer; Gemcitabine for first-line therapy for ovarian, breast, lung and pancreatic cancers; and other cancer support therapeutics, as well as generic sterile injectable cytotoxic products. Its drug development programs include KRN5500, a non-narcotic/non-opioid that has completed Phase IIa clinical trial for the treatment of neuropathic pain in cancer patients; and DB959, which has completed a Phase I study for the treatment of metabolic diseases, including type 2 diabetes and dyslipidemia. The company